Conferences  >  Medicine & Healthcare  >  Immunology and Allergic Diseases

event lab. GmbH

Anlässlich des 28. Europäischen Hämatologen Kongresses werden bei EHA Kompakt in einer dreistündigen, digitalen Veranstaltung die Neuigkeiten des Kongresses der European Hematology Association anschaulich zusammengefasst. Ziel ist es, einen auf das Wesentliche fokussierten und interessanten Überblick zu den Schwerpunkten der Hämatologie zu geben. Dabei wird insbesondere auf klinisch relevante Innovationen im Fachgebiet gesetzt. Anschließend besteht der Raum für eine angeregte wissenschaftliche Diskussion über die neuen Erkenntnisse. Die Veranstaltung ist Teil der Veranstaltungsreihe "Hämatologie Leipzig" der Klinik und Poliklinik für Hämatologie, Zelltherapie und Hämostaseologie des Universitätsklinikums Leipzig. Weitere geplante Veranstaltungen unter: https://leipzig-haematologie.de/

Kongressbüro der event lab. GmbH;     Phone: [+49 341 308884 64];     Email: haematologie-leipzig@eventlab.org

Onkologie, Zelltherapie, Hämostaseologie, Immunologie, Infektiologie

Hematology,    Oncology

Mindspace Conferences

Mindspace Conferences is organizing the International Conference on Immunology and Allergic Diseases, a highly anticipated event for researchers, healthcare professionals, and industry experts who specialize in immunology and allergic diseases. The conference provides a platform for attendees to exchange knowledge, share insights, and discuss the latest advancements in the field. The theme of the Immunology Conference 2025 is “Advances in Immunotherapy for Allergic Diseases,” which reflects the ever-evolving landscape of Immunology and Allergic Diseases.

Program Manager;     Phone: [+44 – 20 3289 8986];     Email: immunology@mindspaceconferences.co.uk

Allergy and Clinical Immunology, Clinical Management of Anaphylaxis, Asthma Management and Control, Immunotoxicology, Immunology of Barrier Surfaces, Immunoassays, Immune System Diseases, Autoimmune Disorders, Immunotherapy for Pediatric Respiratory Allergy, Food Allergy and Intolerance, Tumor Immunology, Immunity and Ageing, Genetics and Epigenetics of Allergic Diseases, Allergy Prevention Strategies, Drug Allergies & Allergic Rhinitis, Immunology Research & Therapies, Computational Immunology, Immunomodulation and Immune Regulation, Immune Development and Aging, Allergy and Hypersensitivity, Anaphylaxis and Emergency Management, Immune Pathology and Pharmacology, Immunology of transplantation, Environmental Allergies, Antigen Research, Allergy Management and Treatment, Allergic conjunctivitis & Hives (urticaria), T cell & B cell Receptors, Psoriasis & Hashimoto’s thyroiditis, Allergens & Eczema (Atopic Dermatitis)

CHI

Commercializing breakthrough immune-oncology therapeutics is becoming increasingly challenging due to funding limitations, high cost and attrition rates in the clinic, regulatory uncertainties, persistent therapeutic safety and efficacy concerns, and a general lack of understanding of basic biology guiding research in this space. As we develop the 2025 conference program, we are struck by the fact that, despite these challenges, there remains a strong desire to continue to find effective therapeutics for solid tumors. The 13th Annual Immuno-Oncology Summit showcases successes in preclinical and clinical studies grounded in a deep understanding of biology. Coverage spans solid tumor innovations, including bi/multispecific antibodies, antibody-drug conjugates (ADCs), allogenic and in vivo CAR-Ts, TILs, TCRs, Tregs, multiple cell therapies working together, the tumor microenvironment, innate immunity, gamma delta T cells, NK cells, organoid modeling, data science, and machine learning. The program also explores autoimmunity as a critical and complementary area of focus.

Phone: [781.972.5400];     Email: chi@healthtech.com

Oncology,    Biotechnology

The European Association for Cancer Research (EACR)

The 6th edition of this conference will focus on cancer models that span in vitro investigations to in vivo cancer biology. It will emphasise how targeting the mechanisms that control tissue assembly – including the interactions with multiple epithelial cell types and the immune system – affects cancer progression and treatment response. Emerging topics also being discussed include mechanobiology, the immune response, how the extracellular matrix controls cell architecture, and how cell fate transitions underpin tissue morphogenesis and the metastatic cascade. The target audience for this conference is scientists, postdocs, and graduate students interested in the latest generation of engineered ex vivo models of tissue biology, in vivo cancer biology, and the use of these mechanobiological concepts for the development of cancer therapeutics. It will also be highly relevant for industry scientists interested in cutting-edge models of cancer and journal editors interested in ex vivo to in vivo models of biology and cancer.

Conference Officer Hannah Barrs;     Phone: [N/A];     Email: hannah.barrs@eacr.org

cancer research, oncology, in vitro models of cancer, ex vivo models of cancer, in vivo models of cancer, the extracellular matrix, cancer cell architecture, mechanobiology, immune response to cancer, tissue morphogenesis, the metastatic cascade, cancer immunotherapies, advanced imaging technologies, organoids, microtissue platforms, spatial transcriptomics, cell fate transitions, homeostasis, cancer progression, cancer therapeutic developments.

Oncology,    Molecular Biology

EMBL Heidelberg

The ability to grow tissues from stem cells in 3D culture to generate so-called organoids has revolutionised the study of tissue biology, especially human biology. This exciting technology has great potential for drug discovery and regenerative medicine. Because organoids model a variety of tissues with remarkably high fidelity, they allow for new discoveries in human development, homeostasis, regeneration, and disease. This symposium will bring together the leading researchers in this field, representing the premier conference for this research community, and providing a much-anticipated program that demonstrates how this field is truly pushing the boundaries for our understanding of tissue biology. This, the fifth edition of this established meeting will again bring together researchers from different fields to enhance our understanding of how organoids can be formed and maintained and their biomedical applications, from how they can be exploited to study disease to eventually use them to regenerate and replace human tissues. An aim for the 2025 edition of the symposium is the incorporation of more complementary technologies, such as multiomics, engineered embryo models and bioengineering as well as increased representation of the topic of cancer.

Inna Bösselmann;     Email: inna.boesselmann@embl.de

AKM Allergiekongress und Marketing GmbH

wikonect GmbH;     Email: allergiekongress@wikonect.de